Equity Profile

GKOS

Glaukos Corporation

Health CareHealth Care Equipment$11.2B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Glaukos Corporation is a healthcare company that develops innovative products for the treatment of eye diseases, particularly glaucoma. With a market cap of $11 billion, it plays a significant role in the health care equipment sector, focusing on improving patient outcomes through advanced surgical solutions.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability, and investors will be keen to see if Glaukos can continue to narrow its losses.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its market presence and product adoption, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GKOS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+18.24%

Avg Stock Reaction

-0.98%

Last Quarter Recap

In Q1 2026, Glaukos reported an EPS of -$0.18, which was better than the expected -$0.30, marking a 39.6% surprise. However, the stock fell by 2.23% the following day, reflecting market caution despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Glaukos are mixed, with the market uncertain about future profitability and revenue growth. Investors are looking for signs of improvement in both metrics.

Bull Case

If Glaukos can show a significant reduction in losses and strong revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations for revenue growth or reports larger-than-expected losses, it could lead to a further decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in assessing whether Glaukos is making progress towards profitability, which investors are closely monitoring.

How is revenue growth trending compared to previous quarters?

Understanding revenue trends will provide insight into the company's market position and product demand, which are key for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Glaukos's potential for revenue growth due to recent product launches that have not yet been fully reflected in analyst models.

Supporting Evidence

The company has a history of beating EPS estimates, suggesting a potential for better-than-expected performance.

Options pricing indicates a higher expected move than historical averages, suggesting traders anticipate significant news.

Recent product innovations may lead to increased market share that analysts have not fully accounted for.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Glaukos's ability to demonstrate financial improvement and market traction.

Bull Confirmed If

An EPS of -$0.10 or better, coupled with revenue growth of at least 15% year-over-year, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.25 and flat or declining revenue would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.87%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move of nearly 8%, indicating that traders expect volatility around the earnings report.

Options are pricing ±7.9% while GKOS has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

81.7%

Calls (15K)P/C Ratio: 0.39Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Glaukos beats expectations, history suggests the stock could rise by an average of 1.17%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is given, the stock may experience minimal movement as investors reassess their outlook.

Miss

If Glaukos misses expectations, the stock could drop by an average of 2.59%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on cost management strategies and their impact on future profitability.
3Insights into competitive pressures and how Glaukos plans to address them.
4Management's outlook on market conditions and potential growth opportunities.
5Any commentary on partnerships or collaborations that could enhance product distribution.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability, and investors will be keen to see if Glaukos can continue to narrow its losses.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its market presence and product adoption, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

GKOS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+18.24%

Avg Stock Reaction

-0.98%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Glaukos are mixed, with the market uncertain about future profitability and revenue growth. Investors are looking for signs of improvement in both metrics.

Bull Case

If Glaukos can show a significant reduction in losses and strong revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations for revenue growth or reports larger-than-expected losses, it could lead to a further decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in assessing whether Glaukos is making progress towards profitability, which investors are closely monitoring.

How is revenue growth trending compared to previous quarters?

Understanding revenue trends will provide insight into the company's market position and product demand, which are key for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Glaukos's potential for revenue growth due to recent product launches that have not yet been fully reflected in analyst models.

Supporting Evidence

The company has a history of beating EPS estimates, suggesting a potential for better-than-expected performance.

Options pricing indicates a higher expected move than historical averages, suggesting traders anticipate significant news.

Recent product innovations may lead to increased market share that analysts have not fully accounted for.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Glaukos's ability to demonstrate financial improvement and market traction.

Bull Confirmed If

An EPS of -$0.10 or better, coupled with revenue growth of at least 15% year-over-year, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.25 and flat or declining revenue would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.87%

Historical Avg

±1.2%

Pricing rich

The options market is pricing in a significant move of nearly 8%, indicating that traders expect volatility around the earnings report.

Options are pricing ±7.9% while GKOS has averaged ±1.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

81.7%

Calls (15K)P/C Ratio: 0.39Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Glaukos beats expectations, history suggests the stock could rise by an average of 1.17%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is given, the stock may experience minimal movement as investors reassess their outlook.

Miss

If Glaukos misses expectations, the stock could drop by an average of 2.59%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market reception.
2Details on cost management strategies and their impact on future profitability.
3Insights into competitive pressures and how Glaukos plans to address them.
4Management's outlook on market conditions and potential growth opportunities.
5Any commentary on partnerships or collaborations that could enhance product distribution.